Evidence map›Paper›PMID 42143173›Full record

ArticleScientific reports2026

Impact of hospital safety-net status on in-hospital and short-outcomes after hematopoietic stem cell transplantation.

Qi Zhang, Hui Wang, Qian Chen, Hongjing Dong, Qiuyan Yu, Na Liu, Wen Li, Nan Zhao, Kui Zhang, Min Fang and 1 more

Abstract read
In one paragraph

Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Qi ZhangDepartment of Hematology, Tengzhou Central People's Hospital, No 181 Xingtan Road, Tengzhou, 277599, Shangdong, China.
Hui WangDepartment of Hematology, Tengzhou Central People's Hospital, No 181 Xingtan Road, Tengzhou, 277599, Shangdong, China.
Qian ChenDepartment of Hematology, Tengzhou Central People's Hospital, No 181 Xingtan Road, Tengzhou, 277599, Shangdong, China.
Hongjing DongDepartment of Hematology, Tengzhou Central People's Hospital, No 181 Xingtan Road, Tengzhou, 277599, Shangdong, China.
Qiuyan YuDepartment of Hematology, Tengzhou Central People's Hospital, No 181 Xingtan Road, Tengzhou, 277599, Shangdong, China.
Na LiuDepartment of Hematology, Tengzhou Central People's Hospital, No 181 Xingtan Road, Tengzhou, 277599, Shangdong, China.
Wen LiDepartment of Hematology, Tengzhou Central People's Hospital, No 181 Xingtan Road, Tengzhou, 277599, Shangdong, China.
Nan ZhaoDepartment of Hematology, Tengzhou Central People's Hospital, No 181 Xingtan Road, Tengzhou, 277599, Shangdong, China.
Kui ZhangDepartment of Hematology, Tengzhou Central People's Hospital, No 181 Xingtan Road, Tengzhou, 277599, Shangdong, China.
Min FangDepartment of Hematology, Tengzhou Central People's Hospital, No 181 Xingtan Road, Tengzhou, 277599, Shangdong, China. fangdamin2023@126.com.
Chi ZhouDepartment of Cardiology, The Affiliated Hospital of Qingdao University, Shinan District, No 16 Jiangsu Road, Qingdao, 266003, Shandong, China. 13206397160@163.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Safety-net hospitals (SNHs) cater to the medical needs of underserved populations, but their impact on the outcomes of hematopoietic stem cell transplantation (HSCT) remains unclear. The aim of this study was to evaluate the relationship between safety-net status and posttransplant outcomes using the National Readmission Database (NRD), including in-hospital mortality, in-hospital complications, and readmission. This was a retrospective cohort study. Adult patients who underwent allogeneic or autologous HSCT were identified using ICD-9 and ICD-10 procedure codes. Hospitals were classified as SNHs or non-SNHs based on the proportion of Medicaid patients they served. A total of 30,924 patients were treated in the SNHs group and 99,582 in the non-SNHs group. The incidence of in-hospital complications was higher in SNHs. Among those who underwent autologous HSCT (auto-HSCT), in-hospital mortality (2.7% vs. 2.3%; OR = 1.14, 95% CI: 1.02-1.27; P = 0.024) and 30-day readmission rates (16.3% vs. 15.2%; aOR = 1.05, 95% CI: 1.02-1.09; P < 0.001) were modestly higher in SNHs. Similarly, among patients undergoing allogeneic HSCT (allo-HSCT), those treated at SNHs had slightly higher in-hospital mortality (6.5% vs. 5.1%; OR = 1.24, 95% CI: 1.07-1.44; P < 0.001) and 30-day readmission rates (31.6% vs. 28.0%; aOR = 1.13, 95% CI: 1.05-1.23; P = 0.002). However, the magnitude of these differences was modest. These findings should be interpreted with caution given the observational design. While the results may suggest potential disparities in care, further studies are needed to clarify whether the observed differences are driven by patient-level or hospital-level factors and to determine whether targeted interventions may be beneficial.

Indexed as

Hematopoietic Stem Cell TransplantationSafety-net ProvidersAdultFemaleHospital MortalityHumansMaleMiddle AgedPatient ReadmissionRetrospective StudiesTransplantation, AutologousTreatment OutcomeUnited StatesClinical outcomesHematopoietic stem cell transplantationNational readmission databaseReadmissionSafety‐net hospitals

Identifiers

PMID42143173
PMCPMC13376780

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.